Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease (DECODE)

21. února 2017 aktualizováno: University of Surrey

DNA Damage and Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease

The purpose of this study is:

  1. To examine the association between stable and unstable coronary artery disease (CAD) with markers of DNA damage and repair,
  2. To examine the association between plaque morphology as assessed by frequency-domain optical coherence tomography (FD-OCT) and markers of DNA damage and repair in order to identify potential markers of plaque instability,
  3. To examine the association between markers of DNA damage and repair and major adverse cardiovascular events defined as death, MI and unplanned percutaneous or surgical revascularization,

Přehled studie

Postavení

Dokončeno

Detailní popis

Hypotheses ----------------

We hypothesise that defective DNA damage response is an important aetiological factor in the development of CAD, underlying CAD severity and development. If this hypothesis is true, then we predict that:

  1. There is differential expression of markers of DNA damage and repair in patients with stable angina, a model of stable CAD, and patients with non ST-elevation myocardial infarction (NSTEMI), a model of unstable CAD.
  2. Differential expression of markers of DNA damage and repair correlate with plaque morphology and stability as defined by FD-OCT,
  3. Markers of DNA damage and repair can serve as distinguishing markers of stable and unstable CAD,

    Methodology

    ------------------

    Study Population:

    Patients presenting with stable angina undergoing percutaneous revascularization at Ashford and St. Peter's Hospitals Foundation Trust will be prospectively enrolled. Data regarding demographic, clinical, and procedural characteristics of patients will be collected by the Ashford and St. Peter's Hospitals Foundation Trust research personnel and entered into a secure, encrypted, dedicated database.

    Pre-defined clinical and angiographic inclusion and exclusion criteria will be met as per the DECODE study protocol.

    FD-OCT (St. Jude Medical ILUMIEN OCT System) will be performed in all the three main epicardial coronary arteries prior to target vessel PCI after administration of glyceryl trinitrate. Data will be acquired in a designated, secure compute and sent to a corelab for analysis. Quantitative measurements will include endoluminal area, plaque area, as well as plaque parameters including thin- capped fibroatheromas (TCFA), fibrous tissue, lipid core and calcium. TCFA will be defined by lipid-rich plaque with cap thickness ≤ 65μm.

    Culprit lesions will be defined according to electrocardiographic criteria (ST-segment shift or T-wave inversion) and angiographic appearances (luminal irregularities consistent with lesion ulceration, filling defect(s) consistent with thrombus, or point of angiographic maximal stenosis) in patients with NSTEMI and angiographic stenosis ≥ 70% in patients with stable angina not responding to at least two anti-anginal medications.

    Blood will be drawn immediately prior to percutaneous coronary intervention. In addition to routine haematological and biochemical parameters (complete blood count, white cell count, platelet count, creatinine, urea, sodium, potassium, cholesterol, glucose, troponine I, creatinine phosphokinase, liver function tests and clotting screen) one additional blood sample will be taken and separated into plasma and serum. Polymorphonuclear leukocytes will be used for measurements of DNA damage and repair proteins.

    Clinical follow-up will occur at 30-day and 12-month from enrolment by telephone interview and clinic visits. A repeat blood sample will be taken for analysis of DNA damage and repair proteins.

    DNA Damage

    ------------------

    DNA damage will be analysed by measuring DNA strand breaks in cell pellets using the comet assay. Serum oxidised purines will also be measured using an ELISA based assay. The transcriptional activation of DNA damage proteins will be assessed by real time PCR. For this, RNA will be isolated using a Roche High Pure Isolation kit. The RT2 First Strand Kit (SABioscience) will be utilised for reverse transcription of total RNA. Automated PCR will be set up and the raw data will be normalised using the average cycle threshold (ct) value of four housekeeping genes (B2M, RPL13A, GAPDH, and ACTB).

    Whether differential gene expression leads to differential protein expression will be determined by Western blotting. Moreover, the phosphorylation status of DNA damage proteins will also be assessed.

    DNA repair activity will also be assessed for several DNA repair enzymes important for the repair of base damage generated by reactive oxygen and nitrogen species. DNA repair activity will be measured by using in-vitro oligonucleotide-based cleavage assays.

    Finally, we will then correlate measures of DNA damage and repair with patient presentation (stable angina vs. NSTEMI), MACE, and FD-OCT derived parameters including the number of TCFA, plaque volume and percentage of plaque components.

    Statistical analysis

    -------------------------

    Statistical analysis will be performed using SAS version 8.2 (SAS institute Inc., Cary, North Carolina). Biomarker parameters will be tested for an association with patient presentation (stable angina vs. NSTEMI) and MACE using a log-rank test. OCT derived parameters will be tested for an association with biomarkers using univariate Cox proportional hazard regression. Parameters with a significance level of ≤0.1 on univariate analysis will undergo multivariate Cox proportional hazard analysis. A p value <0.05 will be considered statistically significant.

    The recruitment period is anticipated to last 15-18 months, with data collation and interpretation throughout recruitment and analysis anticipated to be complete by 24 months.

Typ studie

Pozorovací

Zápis (Aktuální)

126

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Surrey
      • Chertsey, Surrey, Spojené království, KT16 0PZ
        • Ashford and St. Peter's Hospital
      • Guildford, Surrey, Spojené království, GU2 7XH
        • University of Surrey

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Patients presenting with stable angina (n=50) or NSTEMI (n=50) undergoing percutaneous revascularization at Ashford and St. Peter's Hospitals Foundation Trust will be prospectively enrolled. Data regarding demographic, clinical, and procedural characteristics of patients will be collected by the Ashford and St. Peter's Hospitals Foundation Trust research personnel and entered into a secure, dedicated database. Results will be compared to age and sex matched controls

Popis

Inclusion Criteria

-----------------------

Clinical:

  1. Age ≥ 18 years
  2. Stable angina not responding to at least two anti-anginal medications (beta blockers, calcium channel antagonists, long acting nitrate, Nicorandil, Ivabradine, or Ranolazine), or NSTEMI.
  3. Patient is able to provide written, informed consent and is able to follow protocol procedures.

Angiographic:

1. Successful and uncomplicated percutaneous coronary intervention (PCI) performed in the major epicardial coronary arteries.

NB: Successful PCI is defined as residual diameter stenosis < 5% in all treated lesions with thrombolysis in myocardial infarction (TIMI)-3 flow (defined as normal flow which fills the distal coronary bed completely), absence of intraprocedural chest pain or ST-segment changes lasting > 10 minutes, persistent vessel closure, no re-flow, perforation, dissection or requirement for cardiopulmonary resuscitation, defibrillation, pacemaker or intra-aortic balloon implantation.

Exclusion Criteria:

------------------------

Clinical:

  1. Presentation with ST-elevation MI (STEMI),
  2. Decompensated heart failure, hypotension, shock, refractory ventricular tachycardia, acute conduction disorders, left ventricular ejection fraction ≤ 30%,
  3. Prior coronary revascularization,
  4. Any form of surgery up to three months prior to enrolment,
  5. Active inflammatory disorders,
  6. Bleeding diathesis,
  7. Known allergy, hypersensitivity, or contraindication to aspirin, heparin, or thienopyridines,
  8. Life expectancy less than 1 year,
  9. Diabetes mellitus.

Angiographic:

  1. Left main coronary artery stenosis ≥ 50%,
  2. Coronary artery bypass surgery planned within one year of the PCI,
  3. Anatomical conditions precluding three-vessel FD-OCT (significant tortuosity, severe calcification, chronic total occlusion).

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Stable angina patients

Patients with stable angina not responding to 2 anti-anginals presenting for coronary angiography with the possibility of proceeding to stent implantation at Ashford and St. Peter's Hospital.

Clinical and angiographic exclusion criteria as stated in the study protocol.

NSTEMI patients

Patients presenting to Ashford and St. Peter's Hospital with an non ST-elevation myocardial infarction defined by :

Detection of a rise and/or fall of cardiac biomarker values (troponin I) with at least one value above the 99th percentile upper reference limit at analysing laboratories at Ashford and St. Peter's Hospital along with at least one of the following:

  • Symptoms of ischaemia
  • Development of pathologic Q waves in the electrocardiogram (ECG)
  • New or presumed new significant ST-segment-T wave (ST-T) changes on ECG.
  • Identification of an intracoronary thrombus by angiography.
  • Imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Difference in DNA ligase activity in peripheral blood mononuclear cells of patients with stable angina and non-ST-elevation myocardial infarction
Časové okno: 18 months
DNA ligase (DNA repair enzyme) activity measured using units per well, in peripheral mononuclear cells between stable and NSTEMI patients undergoing percutaneous coronary intervention.
18 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Plaque fibrous cap thickness and its association with major adverse cardiovascular events (MACE)
Časové okno: 18 months
Examine the correlation between markers of DNA damage with plaque morphology and cap thickness, measured in micrometres, as assessed with optical coherence tomography and major adverse cardiac events defined as a composite of death, MI and target lesion revascularisation.
18 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. září 2014

Primární dokončení (Aktuální)

1. října 2016

Dokončení studie (Aktuální)

1. října 2016

Termíny zápisu do studia

První předloženo

28. října 2014

První předloženo, které splnilo kritéria kontroly kvality

6. ledna 2015

První zveřejněno (Odhad)

9. ledna 2015

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

23. února 2017

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

21. února 2017

Naposledy ověřeno

1. února 2017

Více informací

Termíny související s touto studií

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit